

Alexei Nemazany [a] and Norbert Haider*

Institute of Pharmaceutical Chemistry, University of Vienna, Althanstraße 14, A-1090 Vienna, Austria


[a] Kiev Shevchenko University, Chemical Faculty, Volodymyrska Str. 62, Kiev 252017, Ukraine

Received September 3, 1996

Reaction of *N*-substituted amides of 2-chloro- or 4-chloronicotinic acid with CH-acidic nitriles in the presence of a base provides a convenient access to amino derivatives of 1,6-naphthyrid-5(6*H*)-one, compounds of type **4** and **5**, or 2,7-naphthyrid-1(2*H*)-one **7**.



J. Heterocyclic Chem., **34**, 397 (1997).

A few years ago, it has been shown that the reaction of secondary amides of *ortho*-halogenobenzoic acids with substituted acetonitriles like malononitrile, arylacetonitriles or hetarylacetonitriles offers a simple and efficient route to a variety of 4-substituted 3-aminoquinolin-1(2*H*)-ones [1-3], as displayed in Scheme 1.



Our interest in developing synthetic approaches to poly-functional derivatives of condensed *N*-heterocycles now led us to investigate the reaction behavior of such nitrile syntheses towards secondary amides of *ortho*-chloronicotinic acids under alkaline conditions. Thus, treatment of various *N*-alkyl- and *N*-aryl-2-chloronicotinamides of type **1** with malononitrile (**2**) or 2-benzothiazolylacetonitrile (**3**), respectively, in the presence of a base (potassium carbonate, cesium carbonate, or 1,8-diazabicyclo[5.4.0]undec-7-ene) in dimethylformamide solution was found to give rise to the formation of a series of new 7-amino-1,6-naphthyrid-5(6*H*)-ones, compounds **4a-e** and **5a-c**, in reasonable to good yields. Obviously, in a first step the chloro function undergoes nucleophilic substitution by the carbanion generated from the RCH_2CN building block, then the ring is closed by addition of the amide NH function to the cyano group, followed by tautomerization (Scheme 2). This pathway also provides a convenient route to 3-amino-2,7-naphthyrid-1(2*H*)-one derivatives, as exemplified by the smooth conversion of *N*-benzyl-4-chloronicotinamide (**6**) into compound **7**, as displayed in Scheme 3.


Interestingly, when (1-methyl-2-benzimidazolyl)acetonitrile (**8**) is employed as the nitrile component, the reaction takes a different course: in all cases, starting from the amides **1a**, **1b** or **1c**, respectively, we isolated an identical product in 40-60% yield which was identified as the tetracyclic compound **9**; this benzimidazo[1,2-*g*][1,6]naph-



thyridine derivative had been prepared recently by us *via* a different route [4]. This finding may be interpreted in terms of preferential attack of the nucleophilic benzimidazole N-3 atom at the carboxamide function (with loss of RNH_2 , cf. Scheme 4) rather than addition of the amide NH to the nitrile group as in the case of compounds **2** and **3**.

As an extension of the 7-amino-1,6-naphthyridone syntheses described above, we investigated the possibility of combining the first cyclization step (which leads to the naphthyridine skeleton) with a subsequent ring annelation onto the [g] side of the system. This should be feasible if a sufficiently reactive leaving group is present in the *ortho* position at the *N*-phenyl moiety so that the 7-amino group can participate in an intramolecular nucleophilic substitution reaction. Analogous transformations, starting from appropriately substituted 2-chloro-5-nitrobenzoic acid

Scheme 4



anilides had been reported recently [3]. Indeed, when *N*-(2-chloro-5-trifluoromethylphenyl)-2-chloronicotinamide (**1f**) and the nitrile **3** were heated in dimethylformamide in the presence of potassium carbonate, the benzimidazo[1,2-g]-[1,6]naphthyridine derivative **10** could be isolated in 57% yield as the sole reaction product (Scheme 5).

In conclusion, the one-step reaction of secondary amides of *ortho*-chloronicotinic acids with CH-acidic nitriles under basic conditions provides an easy and convenient route to a variety of aminonaphthyridones, in certain cases the reaction leads to higher annelated systems. The structures of all new compounds are supported by their ir and nmr spectra as well as by their

Scheme 5




Table 1
Physical and Analytical Data for Compounds **4a-c**, **5a-c**, **7** and **10**

Compound No.	Method [a]	Reaction time (hours)	Yield (%)	Mp, °C Recrystallization solvent	Molecular Formula	Analysis, % Calcd./Found		
						C	H	N
4a	A	6	73	228	$\text{C}_{16}\text{H}_{12}\text{N}_4\text{O}$	69.55	4.38	20.28
	B	8	65	2-propanol		69.62	4.26	20.31
4b	A	4	54	285	$\text{C}_{15}\text{H}_{10}\text{N}_4\text{O}$	68.69	3.84	21.36
				nitromethane		68.43	3.89	21.40
4c	A	5	52	265	$\text{C}_{16}\text{H}_{12}\text{N}_4\text{O}_2$	65.75	4.14	19.17
	C	7	34	nitromethane		65.48	3.94	19.03
4d	A	5	71	258	$\text{C}_{17}\text{H}_{14}\text{N}_4\text{O}_3$	63.35	4.38	17.38
				2-propanol		63.20	4.12	17.27
4e	A	5	58	244	$\text{C}_{17}\text{H}_{14}\text{N}_4\text{O}$	69.47	4.94	19.06
				DMF	$\times 0.2 \text{ H}_2\text{O}$	69.51	4.60	18.97
5a	A	6	82	193	$\text{C}_{22}\text{H}_{16}\text{N}_4\text{OS}$	68.73	4.19	14.57
	B	7.5	75	nitromethane		68.44	4.41	14.59
5b	A	6	42	253	$\text{C}_{21}\text{H}_{14}\text{N}_4\text{OS}$	68.09	3.81	15.12
	B	7	56	nitromethane		67.80	3.90	15.17
5c	A	10	73	267	$\text{C}_{22}\text{H}_{16}\text{N}_4\text{O}_2\text{S}$	64.82	4.15	13.74
	C	12	61	1-propanol	$\times 0.4 \text{ H}_2\text{O}$	64.74	3.87	13.67
7	A	4	75	247	$\text{C}_{16}\text{H}_{12}\text{N}_4\text{O}$	69.55	4.38	20.28
	B	5	62	acetonitrile		69.47	4.27	20.07
10	A	6	57	255	$\text{C}_{22}\text{H}_{11}\text{F}_3\text{N}_4\text{OS}$	60.55	2.54	12.84
				DMF		60.50	2.53	12.57

[a] See Experimental.

Table 2
IR and ¹H NMR Spectral Data for Compounds 4a-e, 5a-c, 7 and 10

Compound No.	IR (cm ⁻¹)	¹ H NMR (δ, ppm)
4a	3440, 3344, 3262, 3064, 2204, 1682, 1646, 1582, 1550, 1490, 1404, 1296, 1074, 780, 750, 692	8.75 (dd, J = 4.5 Hz and 1.8 Hz, 1H, 2-H), 8.29 (dd, J = 8.1 Hz and 1.8 Hz, 1H, 4-H), 7.61 (broad s, 2H, NH ₂), 7.36-7.13 (m, 6H, 3-H, phenyl-H), 5.40 (s, 2H, CH ₂)
4b	3448, 3330, 3226, 3010, 2204, 1678, 1630, 1594, 1578, 1548, 1490, 1414, 1290, 782, 716	8.77 (dd, J = 4.5 Hz and 1.8 Hz, 1H, 2-H), 8.24 (dd, J = 7.8 Hz and 1.8 Hz, 1H, 4-H), 7.62-7.50 (m, 3H, phenyl 3-H, 4-H, 5-H), 7.42-7.36 (m, 2H, phenyl 2-H, 6-H), 7.20 (dd, J = 7.8 Hz and 4.8 Hz, 1H, 3-H), 6.85 (broad s, 2H, NH ₂)
4c	3448, 3326, 3220, 2204, 1686, 1624, 1582, 1548, 1510, 1488, 1414, 1288, 1248, 1170, 1026, 784	8.75 (dd, J = 4.8 Hz and 1.8 Hz, 1H, 2-H), 8.23 (dd, J = 7.8 Hz and 1.8 Hz, 1H, 4-H), 7.32-7.25 (BB' part of an AA'BB' system, 2H, phenyl 2-H, 6-H), 7.19 (dd, J = 7.8 Hz and 4.8 Hz, 1H, 3-H), 7.14-7.06 (AA' part of an AA'BB' system, 2H, phenyl 3-H, 5-H), 6.86 (broad s, 2H, NH ₂), 3.82 (s, 3H, OCH ₃)
4d	3414, 3322, 3204, 2938, 2204, 1682, 1620, 1582, 1552, 1516, 1478, 1404, 1260, 1240, 1128, 1026, 784	8.75 (dd, J = 4.8 Hz and 1.8 Hz, 1H, 2-H), 8.23 (dd, J = 8.1 Hz and 1.8 Hz, 1H, 4-H), 7.19 (dd, J = 8.1 Hz and 4.8 Hz, 1H, 3-H), 7.10 (d, J = 8.7 Hz, 1H, phenyl 5-H), 7.02 (d, J = 2.1 Hz, 1H, phenyl 2-H), 6.93-6.85 (m, 3H, NH ₂ , phenyl 6-H), 3.82 (s, 3H, 4-OCH ₃), 3.73 (s, 3H, 3-OCH ₃)
4e	3382, 3346, 3228, 2206, 1670, 1656, 1594, 1582, 1548, 1500, 1418, 1132, 784	8.71 (dd, J = 4.8 Hz and 1.8 Hz, 1H, 2-H), 8.24 (dd, J = 8.1 Hz and 1.8 Hz, 1H, 4-H), 7.70 (broad s, 2H, NH ₂), 7.33-7.19 (m, 5H, phenyl-H), 7.16 (dd, J = 8.1 Hz and 4.8 Hz, 1H, 3-H), 4.35-4.26 (m, 2H, NCH ₂ CH ₂ C), 2.90-2.81 (m, 2H, NCH ₂ CH ₂ C)
5a	3466, 3050, 1668, 1592, 1566, 1492, 1452, 1422, 1290, 1278, 960, 788, 760, 692	8.96 (dd, J = 4.8 Hz and 1.8 Hz, 1H, 2-H), 8.49 (dd, J = 7.8 Hz and 1.8 Hz, 1H, 4-H), 8.02 (d, J = 7.8 Hz, 1H, benzothiazole 4-H), 7.85 (d, J = 7.8 Hz, 1H, benzothiazole 7-H), 7.46-7.22 (m, 8H, 3-H, benzothiazole 5-H, 6-H, phenyl-H), 5.55 (s, 2H, CH ₂)
5b	3464, 3050, 1668, 1592, 1566, 1492, 1452, 1422, 1290, 960, 788, 760, 692	8.97 (dd, J = 4.8 Hz and 1.8 Hz, 1H, 2-H), 8.42 (dd, J = 8.1 Hz and 1.8 Hz, 1H, 4-H), 8.03 (d, J = 7.8 Hz, 1H, benzothiazole 4-H), 7.78 (d, J = 7.8 Hz, 1H, benzothiazole 7-H), 7.69-7.56 (m, 3H, phenyl 3-H, 4-H, 5-H), 7.51-7.46 (m, 2H, phenyl 2-H, 6-H), 7.45-7.38 (m, 1H, benzothiazole 6-H), 7.33-7.27 (m, 2H, 3-H, benzothiazole 5-H)
5c	3450, 3052, 1676, 1602, 1570, 1494, 1452, 1424, 1290, 1250, 1032, 788, 758	8.94 (dd, J = 4.5 Hz and 1.8 Hz, 1H, 2-H), 8.40 (dd, J = 7.8 Hz and 1.8 Hz, 1H, 4-H), 8.02 (d, J = 7.8 Hz, 1H, benzothiazole 4-H), 7.77 (d, J = 7.8 Hz, 1H, benzothiazole 7-H), 7.46-7.34 (m, 3H, benzothiazole 6-H, phenyl 2-H, 6-H), 7.32-7.23 (m, 2H, 3-H, benzothiazole 5-H), 7.20-7.14 (AA' part of an AA'BB' system, 2H, phenyl 3-H, 5-H), 3.86 (s, 3H, OCH ₃)
7	3414, 3198, 3062, 2200, 1685, 1654, 1602, 1576, 1532, 1496, 1192, 976, 730	9.03 (s, 1H, 8-H), 8.53 (d, J = 5.7 Hz, 1H, 6-H), 7.91 (broad s, 2H, NH ₂), 7.36-7.14 (m, 6H, 5-H, phenyl-H), 5.38 (s, 2H, CH ₂)
10	3066, 1678, 1616, 1560, 1534, 1458, 1306, 1274, 1236, 1110, 1048, 976, 780, 672	13.62 (broad s, 1H, NH), 9.03 (dd, J = 4.8 Hz and 1.8 Hz, 1H, 2-H), 8.84 (s, 1H, 7-H), 8.71 (dd, J = 7.8 Hz and 1.8 Hz, 1H, 4-H), 8.12-7.98 (m, 3H, 9-H, benzothiazole 4-H, 7-H), 7.54-7.48 (m, 1H, benzothiazole 5-H or 6-H), 7.43 (dd, J = 7.8 Hz and 4.8 Hz, 1H, 3-H), 7.37-7.31 (m, 1H, benzothiazole 6-H or 5-H)

microanalyses; details are given in the Experimental and in Tables 1 and 2.

EXPERIMENTAL

Melting points were determined in a capillary tube and are uncorrected. The IR spectra were recorded for potassium bromide pellets on a Perkin-Elmer 1605 FT-IR spectrophotometer. The ¹H NMR spectra were obtained on a Varian Unityplus 300 (300 MHz) spectrometer, using deuteriodimethyl sulfoxide as the solvent. For TLC, Merck aluminium sheets pre-coated with Kieselgel 60 F₂₅₄ were used (eluent: chloroform/methanol, 9:1). Elemental analyses were performed at the Microanalytical Laboratory, Institute of Physical Chemistry, University of Vienna.

Potassium carbonate and cesium carbonate were freshly dried over an open flame and ground before use. Hetarylacetonitriles were prepared according to literature procedures: (1-methyl-2-benzimidazolyl)acetonitrile (8) [6,7] and 2-benzothiazolylacetonitrile (3) [8]. The 2-chloronicotinamides 1a-f and 4-chloronicotinamide 6 were prepared according to known procedures [9,11].

General Procedure for the Preparation of the Aminonaphthyridones 4a-e, 5a-c, 7 and the Condensed Naphthyridones 9 and 10.

Method A.

A mixture of the nitrile 2, 3, or 8 (10 mmoles), a suitable 2- or 4-chloronicotinamide, 1a-f or 6, respectively, (15 mmoles) and 2.07 g (15 mmoles) of potassium carbonate in 40 ml of dimethylformamide was stirred at reflux temperature for 4 to 12 hours. After cooling, the solvent was removed under reduced pressure. Water (25 ml) was added, and the reaction mixture was neutralized (pH 6-7) by addition of acetic acid. The precipitate was collected by filtration, washed with cold water, dried and recrystallized from a suitable solvent. For reaction times and yields, physical, analytical, and spectral data see Tables 1 and 2.

Method B.

The same reaction conditions were applied except that 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (2.28 g, 15 mmoles) was used as a base.

Method C.

The same reaction conditions were applied except that cesium carbonate (4.89 g, 15 mmoles) was used as a base.

7-Amino-6-benzyl-8-cyano-1,6-naphthyrid-5(6H)-one (4a).

This compound was obtained from *N*-benzyl-2-chloronicotinamide (**1a**) and malononitrile (**2**) as colorless crystals.

7-Amino-8-cyano-6-phenyl-1,6-naphthyrid-5(6*H*)-one (**4b**).

This compound was obtained from *N*-phenyl-2-chloronicotinamide (**1b**) and malononitrile (**2**) as colorless crystals.

7-Amino-8-cyano-6-(4-methoxyphenyl)-1,6-naphthyrid-5(6*H*)-one (**4c**).

This compound was obtained from *N*-(4-methoxyphenyl)-2-chloronicotinamide (**1c**) and malononitrile (**2**) as colorless crystals.

7-Amino-8-cyano-6-(3,4-dimethoxyphenyl)-1,6-naphthyrid-5(6*H*)-one (**4d**).

This compound was obtained from *N*-(3,4-dimethoxyphenyl)-2-chloronicotinamide (**1d**) and malononitrile (**2**) as colorless crystals.

7-Amino-8-cyano-6-(2-phenylethyl)-1,6-naphthyrid-5(6*H*)-one (**4e**).

This compound was obtained from *N*-(2-phenylethyl)-2-chloronicotinamide (**1e**) and malononitrile (**2**) as almost colorless crystals.

7-Amino-8-(2-benzothiazolyl)-6-benzyl-1,6-naphthyrid-5(6*H*)-one (**5a**).

This compound was obtained from *N*-benzyl-2-chloronicotinamide (**1a**) and 2-benzothiazolylacetonitrile (**3**) as yellow crystals.

7-Amino-8-(2-benzothiazolyl)-6-phenyl-1,6-naphthyrid-5(6*H*)-one (**5b**).

This compound was obtained from *N*-phenyl-2-chloronicotinamide (**1b**) and 2-benzothiazolylacetonitrile (**3**) as yellow crystals.

7-Amino-8-(2-benzothiazolyl)-6-(4-methoxyphenyl)-1,6-naphthyrid-5(6*H*)-one (**5c**).

This compound was obtained from *N*-(4-methoxyphenyl)-2-chloronicotinamide (**1c**) and 2-benzothiazolylacetonitrile (**3**) as yellow crystals.

3-Amino-2-benzyl-4-cyano-2,7-naphthyrid-1(2*H*)-one (**7**).

This compound was obtained from *N*-benzyl-4-chloronicotinamide (**6**) and malononitrile (**2**) as colorless crystals.

12-Cyano-5,11-dihydro-11-methylbenzimidazo[1,2-*g*]1,6-naphthyrid-5-one (**9**) [4].

This compound was obtained in yields of 58% (method A) or 42% (method B), respectively, from *N*-benzyl-2-chloronicotin-

amide (**1a**) and (1-methyl-2-benzimidazolyl)acetonitrile (**8**) as pale yellow crystals, mp 292-293° (lit [4] 292-293°). The same product **9** was obtained in comparable yields when the 2-chloronicotinamides **1b** or **1c** were used as the starting material.

12-(2-Benzothiazolyl)-5,11-dihydro-8-trifluoromethylbenzimidazo[1,2-*g*][1,6]naphthyrid-5-one (**10**).

This compound was obtained from *N*-(2-chloro-5-trifluoromethylphenyl)-2-chloronicotinamide (**1f**) and 2-benzothiazolylacetonitrile (**3**) as yellow crystals.

Acknowledgments.

Financial support (Grant no. 14/49-94/95) of Alexei Nemazany's stay at the Institute of Pharmaceutical Chemistry during summer 1995 by the Faculty of Formal and Nature Sciences at the University of Vienna (Dean: Professor Dr. W. Fleischhacker), is gratefully acknowledged.

REFERENCES AND NOTES

- [a] Present address: Laboratory of Medicinal Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
- [1] A. G. Nemazany, Y. M. Volovenko, T. A. Silaeva and F. S. Babichev, *Dokl. Akad. Nauk Ukr. SSR, Ser. B*, 36 (1989); *Chem. Abstr.*, **114**, 6271h (1991).
- [2] A. G. Nemazany, Y. M. Volovenko, T. A. Silaeva, M. Y. Kornilov and F. S. Babichev, *Khim. Geterotsikl. Soedin.*, 378 (1991); *Chem. Abstr.*, **115**, 158928m (1991).
- [3] A. G. Nemazany, Y. M. Volovenko, T. A. Silaeva, M. Y. Kornilov and F. S. Babichev, *Khim. Geterotsikl. Soedin.*, 1104 (1991); *Chem. Abstr.*, **116**, 194121x (1992).
- [4] A. Nemazany and N. Haider, *J. Heterocyclic Chem.*, **33**, 1147 (1996).
- [5] A. G. Nemazany, Y. M. Volovenko, T. A. Silaeva, M. Y. Kornilov and F. S. Babichev, *Khim. Geterotsikl. Soedin.*, 86 (1992); *Chem. Abstr.*, **118**, 254721w (1993).
- [6] R. A. B. Copeland and A. R. Day, *J. Am. Chem. Soc.*, **65**, 1072 (1943).
- [7] J. Büchi, H. Zwicky and A. Aebi, *Arch. Pharm. (Weinheim)*, **293**, 758 (1960).
- [8] K. Saito, S. Kambe, Y. Nakano, A. Sakurai and H. Midorikawa, *Synthesis*, 210 (1983).
- [9] A. D. Dunn and R. Norrie, *Z. Chem.*, **28**, 248 (1988).
- [10] K. Noda, A. Nakagawa, S. Miyata and H. Ide, Japan. Kokai 76,108,093 (1976); *Chem. Abstr.*, **86**, 155680w (1977).
- [11] W. C. J. Ross, *J. Chem. Soc., C*, 1816 (1966).